The Most Diverse and Comprehensive Participant Populations in HIV Prevention Trials Conducted to Date1,2*†
Designed to Include Key Populations Who Are Disproportionately Impacted by HIV1-4
All study participants were at high risk for acquiring HIV through sex1,2
- Noninferiority trial with the prespecified ability to test for superiority
- 43 sites around the world (N=4,566)1
Gender and sexuality1:
- 87% of participants were MSM
- 13% were TGW
Age1:
- 68% were <30 years old
Race1:
- 50% in the US were Black
- Superiority trial
- 20 sites around sub-Saharan Africa (N=3,224)2
Age2:
- 50% were <25 years old
Race2:
- 55% had ≥2 sex partners
Adherence you can confirm with as few as 6 in-office injections per year‡
View expert discussion from colleagues
Watch Dr Theo Hodge discuss the efficacy and safety of APRETUDE.
Real HCP compensated by ViiV Healthcare.
*HPTN 083 (N=4,566) was a randomized, double-blind, controlled noninferiority trial of the safety and efficacy of APRETUDE compared with daily oral TDF/FTC for
†HPTN 084 (N=3,224) was a randomized, double-blind, controlled superiority trial of the safety and efficacy of APRETUDE compared with daily oral TDF/FTC for
‡After initiation injections.
HPTN=HIV Prevention Trials Network; MSM=men who have sex with men; PrEP=pre-exposure prophylaxis; TDF/FTC=tenofovir disoproxil fumarate/emtricitabine; TGW=transgender women.
CBTWCNT230041
References:
Landovitz RJ, Donnell D, Clement ME, et al; HPTN 083 Study Team. Cabotegravir for HIV prevention in cisgender men and transgender women.N Engl J Med. 2021;385(7):595-608. doi:10.1056/NEJMoa2101016
Delany-Moretlwe S, Hughes JP, Bock P, et al; HPTN 084 study group. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399(10337):1779-1789. doi:10.1016/S0140-6736(22)00538-4
HIV diagnoses. Centers for Disease Control and Prevention. Updated June 21, 2023. Accessed August 2, 2023. https://www.cdc.gov/hiv/statistics/overview/in-us/diagnoses.html
In Danger: Global AIDS Update 2022. Joint United Nations Programme on HIV/AIDS (UNAIDS); 2022. Accessed August 2, 2023. https://www.unaids.org/en/resources/documents/2022/in-danger-global-aids-update
Koss CA, Hosek SG, Bacchetti P, et al. Comparison of measures of adherence to human immunodeficiency virus preexposure prophylaxis among adolescent and young men who have sex with men in the United States. Clin Infect Dis. 2018;66(2):213-219. doi:10.1093/cid/cix755